Advertisement

Endocrine

, Volume 57, Issue 1, pp 187–188 | Cite as

“Pseudo-progression” in advanced thyroid cancer in response to kinase inhibitor therapy

  • Sina JasimEmail author
  • Mark A. Nathan
  • Keith C. Bible
Endocrine Imaging

References

  1. 1.
    M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621–630 (2015)CrossRefGoogle Scholar
  2. 2.
    C. Sachpekidis, L. Larribere, L. Pan et al., Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur. J. Nucl. Med. Mol. Imaging 42(3), 386–396 (2015)CrossRefGoogle Scholar
  3. 3.
    S. Kebir, R. Fimmers, N. Galldiks, Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET. Clin. Cancer Res. 22(9), 2190–2196 (2016)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Mayo Clinic MinnesotaRochesterUSA

Personalised recommendations